tirzepatide 1.5 mg dosage Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are Microdosing Tirzepatide Chart: A Weekly

Consult with a healthcare provider for guidance in these situations

The universal design means no one feels left behind, regardless of their starting point or familiarity with health systems

Keep your healthcare provider informed of any consistent patterns with injection site issues

Incorrect signatures or a lack of witness confirmation, impacting validity

The clinical trial results from using Wegovy have led it to be touted as a blockbuster drug, just like Ozempic, though the latter was designed to be an antidiabetic drug

But they happen frequently because patients make assumptions that do not survive contact with their actual vial